Abstract: Objective To systematically evaluate the efficacy and safety of magnesium isoglycyrrhizinate in
treatment of severe hepatitis patients with liver failure. Methods The relevant randomized controlled trials
were searched throughout PubMed, Cochrane Library, Embase, WanFang database, Chinese VIP database,
CBMdisc database and CNKI database from January 1990 to July 2016. Trials comparing the efficacy
of magnesium isoglycyrrhizinate versus other glycyrrhizin in severe hepatitis patients with liver failure
were included. The methodological quality and data extraction of included trials were completed by two
independent investigators. Meta-analysis was performed with Review Manager Software 5.2. Results Six
eligible trials including 565 patients were included and assessed. According to the results of meta-analysis,
magnesium isoglycyrrhizinate was remarkably more effective than other glycyrrhizin in terms of alanine
transaminase (ALT), total bilirubin (TBil), prothrombin time (PT) and the incidence rate of adverse reaction
(P ＜ 0.05). Conclusions Magnesium isoglycyrrhizinate is more effective and safe in decreasing the levels of
ALT, TBil, PT and the incidence rate of adverse reaction in patients with severe hepatitis liver failure.